SWOG clinical trial number
SWOG-9219
A Phase II Evaluation of Interleukin-4 (IL-4) in Patients with Non-Hodgkin's Lymphoma
Closed
Phase
Accrual
49%
Published
Research committees
Lymphoma
Treatment
Interleukin-4
Eligibility Criteria Expand/Collapse
biopsy proven low, intermediate or high grade NHL; measurable disease; prior therapy is required as in protocol; no AIDS or HIV; no impaired cardiac status; no CNS involvement
Publication Information Expand/Collapse
2000
Phase II evaluation of interleukin-4 in patients with non-hodgkin's lymphoma: a Southwest Oncology Group trial
Other Clinical Trials
SWOG Clinical Trial Number
S2308
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
S2207
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
12%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase